Mechanisms of drug combinations: interaction and network perspectives

被引:725
作者
Jia, Jia [1 ]
Zhu, Feng [1 ]
Ma, Xiaohua [1 ,2 ]
Cao, Zhiwei W. [2 ]
Li, Yixue X. [2 ]
Chen, Yu Zong [1 ,2 ]
机构
[1] Natl Univ Singapore, Bioinformat & Drug Design Grp, Dept Pharm, Dept Biol Sci,Ctr Computat Sci & Engn, Singapore 117543, Singapore
[2] Shanghai Ctr Bioinformat Technol, Shanghai 201203, Peoples R China
基金
中国国家自然科学基金;
关键词
TYROSINE KINASE INHIBITOR; GROWTH-FACTOR RECEPTOR; HIV-1; REVERSE-TRANSCRIPTASE; SENSITIVE K+ CHANNELS; ATYPICAL RETINOID ST1926; BETA-LACTAM ANTIBIOTICS; TAXOL-INDUCED APOPTOSIS; DNA TOPOISOMERASE-I; BREAST-CANCER; CELL-LINES;
D O I
10.1038/nrd2683
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Understanding the molecular mechanisms underlying synergistic, potentiative and antagonistic effects of drug combinations could facilitate the discovery of novel efficacious combinations and multi-targeted agents. In this article, we describe an extensive investigation of the published literature on drug combinations for which the combination effect has been evaluated by rigorous analysis methods and for which relevant molecular interaction profiles of the drugs involved are available. Analysis of the 117 drug combinations identified reveals general and specific modes of action, and highlights the potential value of molecular interaction profiles in the discovery of novel multicomponent therapies.
引用
收藏
页码:111 / 128
页数:18
相关论文
共 258 条
[1]   Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action [J].
Abal, M. ;
Andreu, J. M. ;
Barasoain, I. .
CURRENT CANCER DRUG TARGETS, 2003, 3 (03) :193-203
[2]   Ara-C affects formation of cancer cell DNA synthesome replication intermediates [J].
Abdel-Aziz, W ;
Jiang, HY ;
Hickey, RJ ;
Malkas, LH .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (04) :312-319
[3]   Celecoxib inhibits interleukin-12 αβ and β2 folding and secretion by a novel COX2-independent mechanism involving chaperones of the endoplasmic reticulum [J].
Alloza, I ;
Baxter, A ;
Chen, Q ;
Matthiesen, R ;
Vandenbroeck, K .
MOLECULAR PHARMACOLOGY, 2006, 69 (05) :1579-1587
[4]   Additive antinociceptive effect of the combination of diazoxide, an activator of ATP-sensitive K+ channels, and sodium nitroprusside and dibutyryl-cGMP [J].
Alves, DP ;
Soares, AC ;
Francischi, JN ;
Castro, MSA ;
Perez, AC ;
Duarte, IDG .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 489 (1-2) :59-65
[5]   Membrane-related effects underlying the biological activity of the anthraquinones emodin and barbaloin [J].
Alves, DS ;
Pérez-Fons, L ;
Estepa, A ;
Micol, V .
BIOCHEMICAL PHARMACOLOGY, 2004, 68 (03) :549-561
[6]   EFFECT OF CAFFEINE ON ERGOTAMINE ABSORPTION FROM RAT SMALL-INTESTINE [J].
ANDERSON, JR ;
DREHSEN, G ;
PITMAN, IH .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1981, 70 (06) :651-657
[7]   DNA arrays as predictors of efficacy of adjuvant/neoadjuvant chemotherapy in breast cancer patients: Current data and issues on study design [J].
Andre, Fabrice ;
Mazouni, Chafika ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2006, 1766 (02) :197-204
[8]   Illuminating drug discovery with biological pathways [J].
Apic, G ;
Ignjatovic, T ;
Boyer, S ;
Russell, RB .
FEBS LETTERS, 2005, 579 (08) :1872-1877
[9]   From drug to protein: using yeast genetics for high-throughput target discovery [J].
Armour, CD ;
Lum, PY .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2005, 9 (01) :20-24
[10]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683